Trial Profile
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Conbercept (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms PANDA-1
- Sponsors Chengdu Kanghong Biotech
- 11 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 08 Oct 2021 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Portugal, according to European Clinical Trials Database. (2021-05-19)